CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase I Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

By
Justin.choi
-
0
34
CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of T1D.
[ViaCyte, Inc.]
Press Release